Last reviewed · How we verify
ECABET
ECABET is a ecabet drug. It is currently in Phase 3 development for Peptic ulcer.
ECABET works by inhibiting pepsin, an enzyme that breaks down food in the stomach.
Ecabet sodium is a small molecule used in clinical trials for conditions such as gastroesophageal reflux disease, delayed bleeding, healing ulcers, quality of ulcers, and dry eye syndromes. It has been studied in combination with lansoprazole for the treatment of gastroesophageal reflux disease in a randomized controlled trial.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ECABET |
|---|---|
| Drug class | ecabet |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine your stomach is like a washing machine, and pepsin is the detergent that breaks down food into smaller pieces. ECABET is like a detergent inhibitor that reduces the amount of pepsin available to break down food, allowing the stomach lining to heal. This helps to reduce inflammation and promote healing in the stomach lining.
Approved indications
- Peptic ulcer
Common side effects
Key clinical trials
- Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease (PHASE2)
- Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome (PHASE2)
- Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome (PHASE2,PHASE3)
- The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease (NA)
- Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ECABET CI brief — competitive landscape report
- ECABET updates RSS · CI watch RSS
Frequently asked questions about ECABET
What is ECABET?
How does ECABET work?
What is ECABET used for?
What drug class is ECABET in?
What development phase is ECABET in?
Related
- Drug class: All ecabet drugs
- Therapeutic area: All drugs in Other
- Indication: Drugs for Peptic ulcer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing